These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 20627371

  • 1. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
    González FJ, Caturla JM, Fernández M, Carrasco R, Marco P, Sánchez J, Benlloch S.
    Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
    [Abstract] [Full Text] [Related]

  • 2. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 3. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 4. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 5. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
    Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA.
    Acta Cardiol; 2011 Aug 01; 66(4):483-8. PubMed ID: 21894805
    [Abstract] [Full Text] [Related]

  • 6. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.
    Thromb Res; 2006 Aug 01; 118(2):189-97. PubMed ID: 16055173
    [Abstract] [Full Text] [Related]

  • 7. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
    Meltzer ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR, Lisman T.
    Haematologica; 2009 Jun 01; 94(6):811-8. PubMed ID: 19377074
    [Abstract] [Full Text] [Related]

  • 8. Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
    Santos IR, Fernandes AP, Carvalho MG, Sousa MO, Ferreira CN, Gomes KB.
    Clin Chim Acta; 2014 Jun 10; 433():76-83. PubMed ID: 24631134
    [Abstract] [Full Text] [Related]

  • 9. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.
    Hamdy M, Shaheen IA, Khallaf M, Selim YMM.
    Pediatr Blood Cancer; 2024 Jun 10; 71(6):e30959. PubMed ID: 38520679
    [Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
    Tàssies D, Roqué M, Monteagudo J, Martorell T, Sionis A, Arzamendi D, Heras M, Reverter JC.
    Thromb Res; 2009 Nov 10; 124(5):614-8. PubMed ID: 19699511
    [Abstract] [Full Text] [Related]

  • 11. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI).
    Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, PRIME Study group.
    Thromb Haemost; 2003 Mar 10; 89(3):554-60. PubMed ID: 12624641
    [Abstract] [Full Text] [Related]

  • 12. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
    Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC.
    J Thromb Haemost; 2005 Oct 10; 3(10):2211-8. PubMed ID: 16092924
    [Abstract] [Full Text] [Related]

  • 13. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.
    Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP.
    Thromb Haemost; 2002 Dec 10; 88(6):1020-5. PubMed ID: 12529754
    [Abstract] [Full Text] [Related]

  • 14. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact.
    Frère C, Morange PE, Saut N, Tregouet DA, Grosley M, Beltran J, Juhan-Vague I, Alessi MC.
    Thromb Haemost; 2005 Aug 10; 94(2):373-9. PubMed ID: 16113828
    [Abstract] [Full Text] [Related]

  • 15. Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions.
    Segev A, Hegele RA, Lau HK, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH.
    Thromb Res; 2004 Aug 10; 114(2):137-41. PubMed ID: 15306156
    [Abstract] [Full Text] [Related]

  • 16. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
    Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP.
    Thromb Haemost; 2003 Jul 10; 90(1):92-100. PubMed ID: 12876631
    [Abstract] [Full Text] [Related]

  • 17. Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.
    Yaoita N, Satoh K, Satoh T, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Miyata S, Kawamura T, Horiuchi H, Fukumoto Y, Shimokawa H.
    Arterioscler Thromb Vasc Biol; 2016 Jun 10; 36(6):1293-301. PubMed ID: 27102961
    [Abstract] [Full Text] [Related]

  • 18. A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.
    Stanne TM, Olsson M, Lorentzen E, Pedersen A, Gummesson A, Gils A, Jood K, Engström G, Melander O, Declerck PJ, Jern C.
    Thromb Haemost; 2018 Feb 10; 118(2):298-308. PubMed ID: 29378355
    [Abstract] [Full Text] [Related]

  • 19. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
    Chengwei X, Xiaoli M, Yuan Z, Li P, Shengjiang W, Chao Y, Yunshan W.
    Blood Coagul Fibrinolysis; 2013 Oct 10; 24(7):698-703. PubMed ID: 23624357
    [Abstract] [Full Text] [Related]

  • 20. Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population.
    Akatsu H, Ishiguro M, Ogawa N, Kanesaka T, Okada N, Yamamoto T, Campbell W, Okada H.
    Microbiol Immunol; 2007 Oct 10; 51(5):507-17. PubMed ID: 17579260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.